TorreyPines Therapeutics Initiates Clinical Trial To Evaluate Analgesic Effect Of Oral Prodrug Of Tezampanel

TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it has initiated a clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of its lead product candidate, tezampanel. The randomized, double-blind, placebo-controlled Phase I trial will enroll 18 healthy volunteers at a single center in the United States.

More: continued here

Filed under: Pain / Anesthetics on June 10th, 2008